新冠疫情中及之后的试验管理:史无前例的挑战与应对
本文由英国试验管理者网络(UKTMN)成员讨论形成,描述新冠疫情期间临床试验管理面临的挑战与调整。试验管理者在患者安全优先、知情同意与招募、数据收集与干预实施等方面承担关键决策与风险应对角色,许多试验暂停招募并采取缓解措施,技术手段提供解决方案,重启试验仍存不确定性,需与申办方、资助方和站点团队协作。
要点
- 疫情期间试验管理者主导风险评估与流程调整,患者安全优先。
- 许多试验暂停招募,同时采取缓解措施维持数据收集。
- 技术手段支持远程与创新流程,经验共享应延续至未来试验设计。
核心结论
- 临床试验团队通过协作快速调整试验流程,同时确保患者安全处于最高优先级。
- 试验管理者在决策、风险评估和流程调整中发挥关键作用。
- 试验社区共享经验与专业知识的做法应延续,使创新实践嵌入未来试验设计与实施。
研究设计与样本
- 本文基于英国试验管理者网络(UKTMN)成员之间的讨论形成,该网络为管理非商业试验的全国性试验管理专业人员网络。
主要发现
- 疫情对临床试验提出广泛挑战,涉及患者安全优先、知情同意与招募新参与者、数据收集与管理以及干预实施。
- 许多情况下招募已暂停,同时采取缓解措施以继续数据收集。
- 技术为应对挑战提供了多种解决方案,试验管理者适应新的工作方式并继续开展临床试验。
- 试验管理组在重启临床试验方面面临新的不确定性,目前尚不清楚重启将如何进行。
临床怎么用
- 试验管理者应与研究团队其他成员密切合作,开展风险评估并调整试验流程。
- 在招募暂停时采取缓解措施以继续数据收集,并利用技术手段支持试验实施。
- 重启试验时,与申办方、资助方和站点团队协作是明确优先事项。
局限性
- 本文基于英国试验管理者网络成员的讨论,未报告系统检索或定量数据。
- 重启临床试验的前景尚不清楚,相关经验具有阶段性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The COVID-19 pandemic has presented unique challenges for the clinical trial community, both in the rapid establishment of COVID-19 clinical trials and many existing non-COVID-19 studies either being temporarily paused (whether that is a complete pause or pause in some activities) and/or adapting their processes. Trial managers have played a key role in decision-making, undertaking risk assessments and adapting trial processes, working closely with other members of the research team. This article presents some of the ways in which trial management processes have been altered and the key role that trial managers have played. It has been born out of discussions between trial managers in the UK who are members of the UK Trial Managers' Network (UKTMN), a national network of trial management professionals managing non-commercial trials.In these unprecedented times, clinical trials have faced many uncertainties and broad-ranging challenges encompassing a range of activities including prioritising patient safety amidst the pandemic, consenting and recruiting new participants into trials, data collection and management and intervention delivery. In many cases, recruitment has been paused whilst mitigations have been put in place to continue data collection. Innovative solutions have been implemented to ensure we continue, where possible, to deliver high-quality clinical trials. Technology has provided many solutions to these challenges, and trial managers have adapted to new ways of working whilst continuing to deliver their clinical trials. Trial management groups are now faced with new uncertainties around re-starting clinical trials, and it is unclear currently how this will go, though working together with sponsors, funders and site teams is clearly a priority.Clinical trial teams have worked together to ensure their trials have adapted quickly whilst ensuring participant safety is given utmost importance. There are clear examples where the trial community have come together to share experiences and expertise, and this should continue in the future to ensure the innovative practices developed become embedded in the design and conduct of clinical trials in the future.
引用
- Mitchell EJ, Ahmed K, Breeman S, et al. It is unprecedented: trial management during the COVID-19 pandemic and beyond. Trials. 2020. PMID: 32917258. doi:10.1186/s13063-020-04711-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。